 89,596 confirmed cases of Mpox have been reported worldwide as of August 2023, with 157 fatalities, primarily affecting young men who have sex with men and individuals with compromised immune systems, including HIV infection and low CD4 count. The approach to managing pox is symptomatic and supportive, but antiviral medications may be necessary for severe or complicated cases. TECOVERAMAT lacks official FDA approval for treating pox in humans, but positive clinical experiences exist, pending ongoing trials. Brincitophover and citophover have also been administered in select cases due to the unavailability of TECOVERAMAT. Observational studies shed light on the utilization of these antiviral agents for managing pox. This article was authored by Giuseppe Bruno and Giovanni Battista Buckeliero.